Evidence map›Paper›PMID 31060529›Full record

Trial reportBMC pulmonary medicine2019

Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial.

James D Chalmers, Megan L Crichton, Gill Brady, Simon Finch, Mike Lonergan, Thomas C Fardon

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02179983 (A Randomized Controlled Trial of Pulmonary Rehabilitation After Exacerbations of Bronchiectasis), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02179983 naterminatednot on this map

A Randomized Controlled Trial of Pulmonary Rehabilitation After Exacerbations of Bronchiectasis

TypeinterventionalSponsorNHS TaysideRan2014 to 2018Enrolled48ConditionsBronchiectasisArmsPulmonary rehabilitation
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Exercise training for bronchiectasis.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospects.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  7. Protected characteristics reported in pulmonary rehabilitation: a scoping review.European respiratory review : an official journal of the European Respiratory Society · 2024
    Article
  8. Exacerbation Prevention and Management of Bronchiectasis.Tuberculosis and respiratory diseases · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

James D ChalmersScottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland. jchalmers@dundee.ac.uk.ORCID http://orcid.org/0000-0001-5514-7868
Megan L CrichtonScottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.
Gill BradyScottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.
Simon FinchScottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.
Mike LonerganScottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.
Thomas C FardonScottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.

Funding

British Lung Foundation GSK/BLF Chair of Respiratory ResearchTenovus (GB) N/A
6 · The paper itself

Abstract

backgroundPulmonary rehabilitation improves exercise capacity and reduces risk of future exacerbation in COPD when performed after an exacerbation. There have been no previous studies of post-exacerbation rehabilitation in bronchiectasis.

methodsParallel group randomized controlled trial compared pulmonary rehabilitation (PR) to standard care (SC) in patients followed an antibiotic treated exacerbation of bronchiectasis. Patients were randomized following a 14 day course of antibiotics was completed. The primary outcome was 6-min walk distance (6 MW) at 8 weeks. Secondary outcomes were time to the next exacerbation, St.Georges Respiratory Questionnaire, COPD CAT score, Leicester cough questionnaire (LCQ) and FEV1 at 8 and 12 weeks post exacerbation.

resultsForty eight patients were enrolled but only 27 had exacerbations within 12 months of enrolment. Nine patients received pulmonary rehabilitation and 18 received standard care. The 6 MW improved significantly from post-exacerbation to 8 weeks in both groups, with no significant difference between PR and SC- mean difference of 11 m (95% CI -34.3 to 56.3,p = 0.6). Time to the next exacerbation was not significantly different hazard ratio 0.83 (0.31-2.19, p = 0.7). No significant differences were seen between groups in terms of LCQ, CAT, FEV1 or SGRQ between groups. An analysis of probability based on the patients enrolled suggested > 1000 subjects are likely be required to have an > 80% probability of observing a statistically significant difference between PR and SC and any such differences would be likely to be too small to be clinically relevant.

conclusionsThis pilot study identified no significant benefits associated with pulmonary rehabilitation after exacerbations of bronchiectasis.

trial registrationNCT02179983, registered on Clinicaltrials.gov 29th June 2014.

Indexed as

Disease ProgressionExerciseAgedAnti-Bacterial AgentsBronchiectasisFemaleHumansMaleMiddle AgedPilot ProjectsProspective StudiesQuality of LifeSeverity of Illness IndexWalk TestAnti-Bacterial Agents

Identifiers

PMID31060529
PMCPMC6501389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.